Sinovac COVID-19 vaccine effective but some data lacking – WHO experts – Reuters

The COVID-19 vaccine produced by Chinas Sinovac Biotech (SVA.O) is efficacious in avoiding COVID-19 in grownups under 60, but some quality information on the risk of severe adverse effects is doing not have, World Health Organization specialists have found.The independent professionals on the WHOs Strategic Advisory Group of Experts (SAGE) reviewed Sinovacs CoronaVac jab from stage 3 clinical trials in China, Brazil, Indonesia, Turkey and Chile.The evaluation came soon after WHO SAGE experts had voiced “really low self-confidence” in information supplied by Chinese state-owned drugmaker Sinopharm on its COVID-19 vaccine relating to the risk of severe side-effects in some patients, but overall confidence in its capability to prevent the illness, a file seen by Reuters showed.”We are really confident that 2 doses of CoronaVac are efficacious in preventing PCR verified COVID19 in adults (18-59 years),” SAGE said in an evaluation published on the WHO website.It mentioned evidence spaces in safety in pregnancy, and on safety and medical security in older grownups, those with underlying disease, and assessment of rare adverse events discovered through post-authorization security monitoring.The professionals said they had a “moderate level of confidence” that the danger of major unfavorable effects was low in individuals aged 59 and less, however had a “low level of confidence” in the quality of evidence that such threat was also low for grownups above 60.